{"id":"NCT02975934","sponsor":"pharmaand GmbH","briefTitle":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","officialTitle":"TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-13","primaryCompletion":"2022-08-25","completion":"2024-08-08","firstPosted":"2016-11-29","resultsPosted":"2023-08-16","lastUpdate":"2025-07-25"},"enrollment":405,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Castration Resistant Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Rucaparib","otherNames":["CO-338"]},{"type":"DRUG","name":"Abiraterone acetate or Enzalutamide or Docetaxel","otherNames":["Zytiga (abiraterone acetate) or Xtandi (enzalutamide) or Taxotere (docetaxel)"]}],"arms":[{"label":"Rucaparib","type":"EXPERIMENTAL"},{"label":"Abiraterone acetate or Enzalutamide or Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.","primaryOutcome":{"measure":"Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration","timeFrame":"From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)","effectByArm":[{"arm":"Rucaparib","deltaMin":11.2,"sd":null},{"arm":"Abiraterone Acetate or Enzalutamide or Docetaxel","deltaMin":6.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":150,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Ireland","Israel","Italy","Spain","United Kingdom"]},"refs":{"pmids":["36795891","36898948","32203306"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":270},"commonTop":["Fatigue","Nausea","Anaemia","Decreased appetite","Diarrhoea"]}}